The cytokines and the B-cell malignancies: a new spin on maximizing therapeutic outcomes

ONS News. 2006;21(8 Suppl):13-4.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antibody-Dependent Cell Cytotoxicity
  • Antineoplastic Agents / therapeutic use
  • Cytokines / therapeutic use*
  • Disease-Free Survival
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Humans
  • Immunologic Factors / therapeutic use
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Lymphoma, B-Cell / diagnosis
  • Lymphoma, B-Cell / therapy*
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / therapy*
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Neoplasm Staging
  • Oncology Nursing / organization & administration
  • Prognosis
  • Remission Induction
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Cytokines
  • Immunologic Factors
  • Rituximab
  • Granulocyte-Macrophage Colony-Stimulating Factor